

Letter from the Editors



Dear Readers, Authors, Reviewer, and Friends:

We are introducing a new journal, "The Journal of SARS-CoV-2 Research, JSCR" (URL: <https://spphllc.com/Sarc-CoV-2/>) and will sponsor all papers about SARS-CoV-2 discovery through the year 2021 (free publications). All papers will be reviewed by the editor and journal board members.

The year 2020 was a year, which will be remembered as a COVID-19 Global disaster through generation to come. This disease has rapidly spread globally since being identified as a public health emergency of major international concern and has now been declared a pandemic by the World Health Organization (WHO). The newly identified zoonotic SARS-CoV-2 is characterized by rapid human-to-human transmission. The SARS-CoV-2 virus has been isolated from asymptomatic individuals, and affected patients continue to be infectious two weeks after cessation of symptoms. The substantial morbidity and socioeconomic impact have necessitated drastic measures across all continents, including nationwide lockdowns and border closures. We felt that it is very important for our publishing service to contribute to the fight against this pandemic and spread new knowledge and research related to SARS-CoV-2 into the medical community.

AASCOV is an open-access medical journal that publishes original research, reviews, case reports, and letters covering a broad field of research relevant to SARS-CoV-2. We intend to publish articles stimulating to read, educate, and inform readers with the most up-to-date research relevant to the journal's scope. Papers about short- and long-term outcomes of the disease, immunization related papers, new treatments will be given priority. The journal's main aim is to spread new knowledge and finding of SARS-CoV-2 among the medical community promptly. Opened discussion, opinions are welcome.

We hope that a new 2021 year will be very fruitful for our goal of knowledge and discovery distribution. We are looking forward to reading, reviewing, and publishing your work. We also are going to preserve it and give DOI links and advertised it widely. We hope you will enjoy working with our editorial team. Manuscripts funded by NIH or their partners will be indexed as PubMed selected citations.

If you are reading this letter, you may well already be on our web. If you are interested in working with us, please, register as an author on the web: <https://spphllc.com/Sarc-CoV-2/user/register>. We will put our talents into work to make your paper well-edited and visible.

Tetyana L. Vasylyeva, MD, PhD
Editor-in-Chief